bli-489
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00820404)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Imipenem-hydrolyzing beta-lactamaseINHIBITOR
nmcA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C([O-])C1=CS[C@@H]2/C(=C\c3cn4c(n3)COCC4)C(=O)N12.[Na+]- Mol. weight
- 327.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4302412 ↗
- ChEMBLCHEMBL4297265 ↗
Also known as
- bli-489
- bli-489
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00909688 | Phase 1 | Jun 1, 2009 | Pfizer, Wyeth |
| NCT00894439 | Phase 1 | May 1, 2009 | Pfizer, Wyeth |
| NCT00854009 | Phase 1 | Feb 1, 2009 | Pfizer, Wyeth |
| NCT00820404 | Phase 1 | Jan 1, 2009 | Pfizer, Wyeth |
Showing 4 of 4 trials
Page 1 / 1